| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
75,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
22,229 |
48,805 |
236,705 |
576,095 |
| Total Sell Value |
$1,027,488 |
$2,098,369 |
$9,481,770 |
$22,449,223 |
| Total People Sold |
3 |
4 |
7 |
10 |
| Total Sell Transactions |
3 |
6 |
11 |
22 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Goldberg Y. Paul |
VP of Clinical Development |
• – – |
2015-09-22 |
4 |
D |
$9.53 |
$79,499 |
D/D |
(8,342) |
28,149 |
|
- |
|
| Goldberg Y. Paul |
VP of Clinical Development |
• – – |
2015-09-22 |
4 |
D |
$9.53 |
$79,499 |
D/D |
(8,342) |
28,149 |
|
- |
|
| Goldberg Y. Paul |
VP of Clinical Development |
• – – |
2015-09-22 |
4 |
OE |
$2.68 |
$98,513 |
D/D |
30,388 |
28,316 |
|
- |
|
| Pimstone Simon N. |
President & CEO |
• • – |
2015-08-18 |
4 |
D |
$11.00 |
$95,458 |
D/D |
(8,678) |
204,205 |
|
- |
|
| Pimstone Simon N. |
President & CEO |
• • – |
2015-08-18 |
4 |
OE |
$4.81 |
$101,594 |
D/D |
20,576 |
210,713 |
|
- |
|
| Robin Sherrington |
SVP Bus. & Corp. Development |
• – – |
2015-08-18 |
4 |
D |
$11.00 |
$14,322 |
D/D |
(1,302) |
3,840 |
|
- |
|
| Robin Sherrington |
SVP Bus. & Corp. Development |
• – – |
2015-08-18 |
4 |
OE |
$4.81 |
$15,189 |
D/D |
3,085 |
4,708 |
|
- |
|
| Holler Frank A |
Director |
– • – |
2015-08-18 |
4 |
D |
$11.00 |
$9,548 |
D/D |
(868) |
174,807 |
|
- |
|
| Holler Frank A |
Director |
– • – |
2015-08-18 |
4 |
OE |
$4.98 |
$10,244 |
D/D |
2,057 |
175,675 |
|
- |
|
| Goldberg Y. Paul |
VP of Clinical Development |
• – – |
2015-08-18 |
4 |
D |
$11.00 |
$14,322 |
D/D |
(1,302) |
6,103 |
|
- |
|
| Goldberg Y. Paul |
VP of Clinical Development |
• – – |
2015-08-18 |
4 |
OE |
$4.81 |
$15,189 |
D/D |
3,085 |
6,971 |
|
- |
|
| Tarnow Michael M |
Director |
– • – |
2015-06-17 |
4 |
OE |
$4.95 |
$7,638 |
D/D |
1,543 |
55,167 |
|
- |
|
| Stein Evan A. |
Director |
– • – |
2015-04-30 |
4 |
A |
$0.00 |
$0 |
I/I |
913,791 |
4,172 |
|
- |
|
| Stein Evan A. |
Director |
– • – |
2015-04-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,038,964) |
0 |
|
- |
|
| Hayden Michael R |
Director |
– • – |
2015-02-03 |
4 |
OE |
$4.81 |
$24,743 |
I/I |
5,144 |
10,288 |
|
- |
|
| Hayden Michael R |
Director |
– • – |
2015-01-08 |
4 |
OE |
$4.98 |
$25,617 |
I/I |
5,144 |
5,144 |
|
- |
|
| Tarnow Michael M |
Director |
– • – |
2015-01-08 |
4 |
OE |
$4.98 |
$25,104 |
D/D |
5,041 |
53,624 |
|
- |
|
| Azab Mohammad |
Director |
– • – |
2015-01-08 |
4 |
OE |
$4.98 |
$12,296 |
D/D |
2,469 |
2,469 |
|
- |
|
| Patou Gary |
Director |
– • – |
2015-01-07 |
4/A |
D |
$22.28 |
$21,233 |
D/D |
(953) |
2,544 |
|
- |
|
| Patou Gary |
Director |
– • – |
2015-01-07 |
4 |
OE |
$4.98 |
$17,415 |
D/D |
3,497 |
3,497 |
|
- |
|
| Mx Associates, Llp |
10% Owner |
– – • |
2014-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,474,660) |
0 |
|
- |
|
| Tarnow Michael M |
Director |
– • – |
2014-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
16,718 |
48,583 |
|
- |
|
| Mx Associates, Llp |
10% Owner |
– – • |
2014-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,474,660 |
1,474,660 |
|
- |
|
| Pimstone Simon N. |
President, CEO and Director |
• • – |
2014-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,878 |
192,307 |
|
- |
|
| Evans Johnston L |
Director |
– • – |
2014-11-09 |
4 |
A |
$0.00 |
$0 |
I/I |
444,655 |
444,655 |
|
- |
|
231 Records found
|
|
Page 9 of 10 |
|
|
